(Q34788230)

4 August 2017

title

Laquinimod, a new oral drug for multiple sclerosis (English)

1 reference

4 August 2017

0 references

2

Brian G Weinshenker

1 reference

4 August 2017

B Mark Keegan

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

371

1 reference

4 August 2017

issue

9630

1 reference

4 August 2017

page(s)

2059-2060

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

4 August 2017

1 reference

7 January 2021

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

MRI monitoring of MS in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960894-6

7 January 2021

10.1016/S0140-6736(08)60894-6

Identifiers

DOI

1 reference

4 August 2017

1 reference